We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+32.51%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$427M
AUM Growth
+$52.8M
Cap. Flow
-$11.7M
Cap. Flow %
-2.75%
Top 10 Hldgs %
60.67%
Holding
34
New
2
Increased
10
Reduced
13
Closed
2

Top Buys

Rank Stock Value
1
ALXO icon
ALX Oncology
ALXO
+$12M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$2.95M
3
IRON icon
Disc Medicine
IRON
+$2.56M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$19.9K
5
INSM icon
Insmed
INSM
+$17.9K

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$5.57M
2
TVTX icon
Travere Therapeutics
TVTX
+$4.94M
3
NTLA icon
Intellia Therapeutics
NTLA
+$4.66M
4
RLAY icon
Relay Therapeutics
RLAY
+$4.39M
5
VERV
Verve Therapeutics
VERV
+$2.72M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.4B
$77.9M 18.23%
7,648,268
– –
IOVA icon
2
Iovance Biotherapeutics
IOVA
$3.63B
$26.7M 6.26%
3,289,470
+2,073
+0.1% +$10.8K
OLMA icon
3
Olema Pharmaceuticals
OLMA
$899M
$26.1M 6.1%
1,857,136
-545
-0% -$7.32K
GERN icon
4
Geron
GERN
$970M
$22.6M 5.29%
10,715,620
+3,139
+0% +$6.1K
ITOS
5
DELISTED
iTeos Therapeutics
ITOS
$19.1M 4.47%
1,745,943
– –
ALXO icon
6
ALX Oncology
ALXO
$277M
$18.8M 4.41%
+1,264,759
New +$12M
MLTX icon
7
MoonLake Immunotherapeutics
MLTX
$1.28B
$17.8M 4.16%
294,576
+386
+0.1% +$19.9K
CRNX icon
8
Crinetics Pharmaceuticals
CRNX
$9B
$17M 3.98%
478,234
-819
-0.2% -$25.1K
KRTX
9
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$16.9M 3.95%
53,279
+69
+0.1% +$13.4K
INSM icon
10
Insmed
INSM
$25.9B
$16.4M 3.83%
528,150
+692
+0.1% +$17.9K
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
$14.4M 3.38%
611,181
+411
+0.1% +$7.32K
RPTX
12
DELISTED
Repare Therapeutics
RPTX
$12M 2.8%
1,639,849
– –
NTLA icon
13
Intellia Therapeutics
NTLA
$1.8B
$11.7M 2.73%
382,598
-162,041
-30% -$4.66M
FOLD
14
DELISTED
Amicus Therapeutics
FOLD
$10.2M 2.38%
715,883
-256
-0% -$2.91K
RGNX icon
15
Regenxbio
RGNX
$638M
$9.86M 2.31%
549,078
-107,640
-16% -$1.9M
MDGL icon
16
Madrigal Pharmaceuticals
MDGL
$12.3B
$9.47M 2.21%
40,910
+51
+0.1% +$8.92K
GPCR icon
17
Structure Therapeutics
GPCR
$3.38B
$9.4M 2.2%
230,696
-65
-0% -$3.73K
AVDL
18
DELISTED
Avadel Pharmaceuticals
AVDL
$9.39M 2.2%
664,986
+762
+0.1% +$8.95K
MORF
19
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$9.35M 2.19%
323,742
+123,742
+62% +$2.95M
HOWL icon
20
Werewolf Therapeutics
HOWL
$45.8M
$9.22M 2.16%
2,388,011
– –
RLAY icon
21
Relay Therapeutics
RLAY
$4.11B
$9.16M 2.14%
832,017
-520,116
-38% -$4.39M
XERS icon
22
Xeris Biopharma Holdings
XERS
$1.55B
$9.04M 2.12%
3,847,232
-140,735
-4% -$260K
VERV
23
DELISTED
Verve Therapeutics
VERV
$8.9M 2.08%
638,163
-219,777
-26% -$2.72M
RVMD icon
24
Revolution Medicines
RVMD
$44.6B
$7.84M 1.83%
273,408
– –
AXSM icon
25
Axsome Therapeutics
AXSM
$10.4B
$7.43M 1.74%
93,387
-199
-0.2% -$13.3K
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q4 2023 Portfolio in Review

As of Q4 2023, MPM BioImpact held 34 positions worth $427M, up 14% from $375M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

MPM BioImpact's Q4 2023 filing shows 2 new, 10 increased, 13 reduced and 2 closed positions. Its largest new stake was ALX Oncology: 1,264,759 shares worth $18.8M. The largest sale was KalVista Pharmaceuticals, an estimated $5.57M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • MPM BioImpact's largest Q4 2023 buy was ALX Oncology: 1,264,759 shares worth $18.8M.
  • MPM BioImpact added most to Morphic Holding, Inc. Common Stock in Q4 2023, an estimated $2.95M increase.
  • MPM BioImpact's biggest Q4 2023 reduction was Intellia Therapeutics, cutting an estimated $4.66M.
  • MPM BioImpact fully exited KalVista Pharmaceuticals in Q4 2023, selling an estimated $5.57M.
  • MPM BioImpact's ten largest holdings make up 61% of its $427M portfolio in Q4 2023.
  • MPM BioImpact opened 2 new positions and closed 2 in Q4 2023.
  • MPM BioImpact's portfolio value rose 14% quarter-over-quarter to $427M.

Based on MPM BioImpact's 13F filing for Q4 2023, filed 13 Feb 2024.